Stay updated with breaking news from Hemodynamic Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - read this article along with other careers information, tips and advice on BioSpace
April 15, 2021 For patients who have pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), treatment with levosimendan (Simdax; Tenax Therapeutics) can improve both pulmonary congestion and submaximal exercise capacity when compared with placebo, according to the results of a small study. While the phase II study missed its primary endpoint, which was a reduction in pulmonary capillary wedge pressure (PCWP) during exercise, levosimendan did reduce PCWPs across the rest, leg raise, and exercise stages. It also led to an improvement in 6-minute walk distance, in...